21/02/2023 - Press release
A study led by researchers at the Hospital del Mar Medical Research Institute shows that the oxaliplatin administered in some cases of colorectal cancer accumulates in non-cancerous/healthy cells from the tumor environment. This accumulation causes healthy cells to produce a protein that further activates them, triggering tumor resistance to treatment and assisting in tumor regeneration. The researchers discovered a marker that can identify these tumors unresponsive to chemotherapy. The study, published in the journal Nature Communications, paves the way for new strategies enhancing the effects of chemotherapy on cancer cells while avoiding adverse side effects on non-cancerous cells.
06/02/2023 - Institutional news
The Hospital del Mar Medical Research Institute will lead one of the studies and will also be one of the main partners in the other three. They will receive funding from the European Union's Horizon Europe program. The LIVERATION project, led by surgeons and researchers from IMIM-Hospital del Mar and Hospital del Mar, will analyse the capacity of state-of-the-art radiofrequency equipment to widen resection margins in liver tumour removal surgery The other projects will explore treatment personalisation after surgery for localised colon cancer (Sagittarius); strategies for reducing childhood obesity in the European Union (OBELISK); and the use of innovative community interventions and new technologies to protect the mental health of Europeans (MENTBEST)
24/01/2023 - Institutional news
The study is being led by Dr. Jaume Marrugat, a researcher at the IMIM-Hospital del Mar and coordinator of the Girona Heart Registry (REGICOR). It will analyse the association of the complete genome with the incidence of cardiovascular diseases in people who do not have this pathology and who have been under observation for more than ten years. This is the first project of its kind to be carried out in southern Europe, with a cohort of more than 101,000 participants from all over Spain, and will enable better personalised prevention of these pathologies in the country.
20/01/2023 - Press release
A person's biological age, in other words, the real age of their body, which is independent of chronological age and which can be measured in specific blood tests, is conditioned by their lifestyle habits. A study by the Neurovascular Research Group at the Hospital del Mar Medical Research Institute, published in the journal Biology, has for the first time associated a higher biological age with the presence of an indicator of brain ageing, white matter hyperintensities, areas of the brain that blood has a harder time reaching. Lifestyle habits influence the DNA configuration and determine biological age. If these habits are modified, DNA ageing and, therefore, biological ageing can be slowed down, thereby decelerating the increase in white matter hyperintensities in brain tissue.
18/01/2023 - General information
The Integrated Pharmacology and Systems Neurosciences Research Group of the Hospital del Mar Medical Research Institute has just published a study in Neurobiology of Disease, in which it highlights the role of the CDK5 protein as a possible marker of early psychosis. Furthermore, this protein is modulated by cannabis use. This paves the way for possible future treatments based on CDK5 expression.
Més informació "Possible biomarker for early psychosis identified"
13/01/23 - Events
The meeting, a success in terms of participation with more than 120 registered participants, has served to analyze the activity of the program and the strategic lines of growth. The Cancer Research Program of the Hospital del Mar Medical Research Institute held its annual meeting this morning, during which the main lines of the program were analyzed and the main challenges for the future were discussed. The initiative has been a success, with more than 120 people registered in the Josep Marull Room.
11/01/2023 - Press release
A study led by researchers from the Stem Cell and Cancer Research Group at the Hospital del Mar Medical Research Institute has revealed the key role a protein plays in identifying patients with T-cell acute lymphoblastic leukaemia who will not respond to standard treatment. The study, published in the journal EMBO Molecular Medicine, shows that combining chemotherapy with an inhibitor for this protein helps to eliminate treatment resistance in an animal model. This is a rare disease, which is diagnosed in around a hundred people each year in Spain, mainly paediatric patients.
22/12/2022 - Institutional news
The Hospital del Mar Medical Research Institute closes a 2022 in which it has strengthened its commitment to the pursuit of quality and the attraction of scientific talent of excellence and young researchers with initiatives such as the new OpenLab. 2022 has been a year full of good news for IMIM-Hospital del Mar. The research carried out has obtained results of great relevance and has had repercussions not only in scientific publications, but also in our society.
22/12/2022 - Institutional news
The European Medicines Agency selected Hospital del Mar Medical Research Institute and the Hospital del Mar to be a Data Partner of the DARWIN EU® data network, an EU-wide federated network of high-quality observational healthcare databases across Europe, that provides expertise and services to support regulatory decision-making throughout the lifecycle of medicinal products. The Hospital del Mar and the Hospital del Mar Medical Research Institute (IMIM) is one of the first eight European centres currently selected to participate in the European Union's DARWIN EU® initiative to carry out multicentre observational studies on medicines. The data available to these partners will be used for studies to generate real-world evidence that will support scientific evaluations and regulatory decision making.
21/12/2023 - Events
Research into immunotherapy for cancer at the Hospital del Mar Medical Research Institute has received a new boost thanks to a donation of 43,250 euros from the Amics de l’Hospital del Mar Foundation. The president of the Amics de l’Hospital del Mar Foundation, Xavier Trias, presented the cheque to the young researchers Marta Bort, Laura Ibáñez and Iván Pérez, on behalf of the research team looking into the Role of Interferon-Gamma in T cell-mediated elimination of breast cancer tumour cells, a project selected through the internal call for proposals "immunotherapy seed". This initiative is aimed at studying, through a proof of concept, some of the molecular mechanisms used by tumour cells to resist immunotherapy, with the goal of improving breast cancer treatments.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
